middl
east
respiratori
syndrom
coronaviru
merscov
new
highli
pathogen
human
coronavirus
emerg
jeddah
saudi
arabia
quickli
spread
countri
middl
east
europ
north
africa
sinc
decemb
infect
least
peopl
fatal
rate
global
result
urgent
need
identifi
antivir
drug
activ
merscov
papainlik
proteas
pl
pro
merscov
repres
import
antivir
target
essenti
viral
matur
also
antagon
interferon
stimul
host
via
deubiquitin
activ
report
discoveri
two
sarscov
pl
pro
inhibitor
well
immunosuppress
drug
mycophenol
acid
abl
inhibit
merscov
pl
pro
inhibit
mechan
mutual
bind
synergist
effect
also
investig
result
identifi
first
time
three
inhibitor
target
merscov
pl
pro
use
lead
compound
antivir
drug
develop
ten
year
outbreak
sever
acut
respiratori
syndrom
sar
hilgenfeld
peiri
new
highli
pathogen
human
coronaviru
cov
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
jeddah
saudi
arabia
viru
quickli
spread
countri
middl
east
europ
north
africa
anderson
baric
chan
et
al
zaki
et
al
viru
caus
symptom
similar
sarscov
also
lead
acut
renal
failur
result
even
deadli
sar
eckerl
et
al
decemb
peopl
infect
mer
led
report
death
http
wwwwhoint
sarscov
merscov
belong
genu
name
betacoronaviru
de
groot
et
al
bat
suspect
origin
reservoir
bat
cov
high
sequenc
similar
sarsand
merscov
identifi
drexler
et
al
ithet
et
al
recent
new
evid
suggest
dromedari
camel
abl
act
zoonot
sourc
viru
haagman
et
al
reusken
et
al
limit
humantohuman
transmiss
also
evid
mer
outbreak
involv
household
hospit
contact
assiri
et
al
signific
number
cluster
sporad
case
origin
multipl
sourc
indic
potenti
futur
outbreak
de
groot
et
al
ithet
et
al
reusken
et
al
situat
mean
urgent
need
identifi
antivir
drug
merscov
order
prepar
futur
outbreak
proteas
one
promin
use
drug
target
antivir
therapi
includ
proteas
human
immunodefici
viru
wens
et
al
hepat
c
viru
hulskott
et
al
kwo
et
al
dengu
viru
steuer
et
al
influenza
zhirnov
et
al
coronavir
proteas
special
main
proteas
ec
papainlik
proteas
pl
pro
ec
consid
suitabl
antivir
target
respons
cleavag
nonstructur
polyprotein
essenti
http
elsevi
bv
right
reserv
abbrevi
afc
cov
coronaviru
dub
deubiquitin
mer
middl
east
respiratori
syndrom
nem
nethylmaleimid
pl
pro
papainlik
proteas
sar
sever
acut
respiratori
syndrom
ub
ubiquitin
viral
matur
larg
number
sarscov
main
proteas
inhibitor
identifi
publish
bacha
et
al
verschueren
et
al
wu
et
al
yang
et
al
zhu
et
al
one
type
proteas
inhibitor
sar
benzotriazol
ester
inhibitor
target
sarscov
main
proteas
drug
identifi
inhibitori
properti
merscov
main
proteas
kilianski
et
al
unlik
drug
broadspectrum
inhibit
main
proteas
inhibitor
sar
initi
screen
exist
sarscov
pl
pro
inhibitor
name
benzodioxolan
deriv
g
merscov
pl
pro
reveal
signific
inhibit
kilianski
et
al
identif
differ
mer
sar
mean
need
understand
structur
function
characterist
merscov
pl
pro
addit
proteolyt
activ
similar
coronavirus
merscov
pl
pro
deubiquitin
dub
isgyl
isg
interferonstimul
gene
activ
yang
et
al
enzym
abl
deubiquitin
interferon
regulatori
factor
prevent
nuclear
transloc
result
suppress
interferon
b
product
end
result
immun
suppress
host
cell
chen
et
al
clementz
et
al
yang
et
al
zheng
et
al
recent
crystal
structur
merscov
pl
pro
free
enzym
merscov
pl
pro
complex
ubiquitin
ub
deriv
publish
studi
pinpoint
uniqu
architectur
oxyanion
hole
merscov
pl
pro
differ
markedli
structur
character
pl
pro
protein
baileyelkin
et
al
lei
et
al
uniqu
featur
subsit
well
flexibl
bind
loop
provid
potenti
drug
target
within
activesit
featur
allow
structurebas
drug
design
report
discoveri
two
sarscov
pl
pro
inhibitor
chou
et
al
well
immunosuppress
drug
mycophenol
acid
abl
inhibit
merscov
pl
pro
inhibit
mechan
mutual
bind
synergist
effect
also
investig
first
three
inhibitor
merscov
pl
pro
describ
find
implic
respect
futur
lead
compound
drug
develop
protein
induct
purif
procedur
sarscov
mutant
sarscov
pl
pro
merscov
pl
pro
describ
previous
chou
et
al
lin
et
al
express
plasmid
merscov
pl
pro
genbank
access
number
polyprotein
residu
includ
tag
cterminu
lin
et
al
briefli
three
express
vector
separ
transform
escherichia
coli
cell
novagen
strain
incub
overnight
induc
mm
isopropylbdthiogalactopyranosid
cell
pellet
resuspend
lysi
buffer
mm
tri
ph
mm
nacl
glycerol
triton
mm
bmercaptoethanol
lyse
sonic
centrifug
remov
insolubl
pellet
next
supernat
incub
ninta
bead
h
allow
supernat
flow
column
bead
wash
wash
buffer
mm
tri
ph
mm
nacl
mm
imidazol
mm
bmercaptoethanol
protein
elut
elut
buffer
mm
tri
ph
mm
nacl
mm
imidazol
mm
bmercaptoethanol
protein
load
onto
gelfiltr
column
ge
healthcar
equilibr
run
buffer
mm
tri
ph
mm
nacl
mm
dithiothreitol
puriti
fraction
collect
analyz
sdspage
protein
concentr
mgml
use
amicon
centrifug
filter
millipor
dub
assay
carri
describ
previous
chou
et
al
lin
et
al
briefli
fluorogen
substrat
ubafc
boston
biochem
lm
incub
without
chemic
compound
mm
phosphat
ph
min
addit
merscov
sarscov
pl
pro
lm
enzymat
activ
determin
continu
monitor
use
fluoresc
emiss
excit
wavelength
nm
respect
perkinelm
ls
luminesc
spectromet
usa
fluorogen
peptidyl
substrat
dabcylfrlkggapikgvedan
use
measur
enzymat
activ
merscov
sarscov
pl
pro
well
mutant
sarscov
pl
pro
describ
previous
chou
et
al
lin
et
al
specif
enhanc
fluoresc
emiss
upon
substrat
cleavag
monitor
use
excit
emiss
wavelength
nm
respect
perkinelm
ls
luminesc
spectromet
fluoresc
intens
convert
amount
hydrolyz
substrat
use
standard
curv
drawn
fluoresc
measur
welldefin
concentr
dabcylfrlkgg
apikgvedan
peptid
ratio
approach
also
correct
inner
filter
effect
substrat
inhibit
studi
reaction
mixtur
contain
lm
peptid
substrat
lm
mm
phosphat
ph
lm
peptid
substrat
lm
mycophenol
acid
mm
phosphat
ph
total
volum
ml
addit
enzym
reaction
mixtur
increas
fluoresc
continu
monitor
increas
fluoresc
linear
least
min
thu
slope
line
repres
initi
reaction
veloc
v
inhibit
data
found
best
fit
competit
inhibit
pattern
accord
eq
inhibit
data
mycophenol
acid
found
best
fit
noncompetit
inhibit
pattern
accord
eq
k
cat
rate
constant
e
denot
enzym
substrat
inhibitor
concentr
k
michaelismenten
constant
interact
peptid
substrat
enzym
k
slope
inhibit
constant
enzymeinhibitor
complex
program
sigmaplot
systat
softwar
inc
usa
use
data
analysi
character
mutual
effect
inhibitor
activ
pl
pro
first
measur
without
either
lm
lm
presenc
variou
concentr
mycophenol
acid
lm
activ
pl
pro
measur
without
lm
mycophenol
acid
lm
variou
nem
concentr
lm
peptidyl
substrat
enzym
concentr
held
lm
respect
data
obtain
multipl
inhibit
reaction
fit
eq
v
initi
veloc
presenc
inhibitor
j
concentr
two
inhibitor
v
veloc
absenc
inhibitor
k
k
j
appar
dissoci
constant
two
inhibitor
measur
degre
interact
two
inhibitor
yonetani
theorel
comput
model
pl
pro
complex
mycophenol
acid
crystal
structur
merscov
pl
pro
pdb
code
use
templat
describ
previous
chen
et
al
chou
et
al
dock
perform
use
ds
model
softwar
accelri
dock
space
near
catalyt
triad
chosen
dock
structur
mycophenol
acid
creat
separ
specifi
input
ligand
dock
chemic
flexibl
ligand
allow
grid
extens
site
nonbond
cutoff
distanc
set
respect
dock
result
calibr
use
mont
carlo
trial
possibl
pose
ten
compar
energi
minim
pose
lowest
bind
energi
chosen
bind
model
previou
studi
indic
two
thiopurin
analog
abl
inhibit
sarscov
pl
pro
bind
site
close
catalyt
triad
chou
et
al
recent
hilgenfeld
colleagu
determin
structur
merscov
pl
pro
xray
crystallographi
lei
et
al
confirm
sar
mer
pl
pro
protein
similar
architectur
albeit
show
sequenc
ident
similar
find
led
us
specul
thiopurin
analog
might
abl
inhibit
merscov
pl
pro
two
pl
pro
possess
similar
catalyt
triad
addit
anoth
preexist
drug
mycophenol
acid
identifi
effect
antimerscov
agent
chan
et
al
although
detail
drug
antivir
effect
mechan
remain
unclear
present
studi
evalu
inhibitori
effect
three
compound
merscov
pl
pro
use
peptid
substrat
ubafc
found
mycophenol
acid
independ
abl
inhibit
effect
proteolyt
activ
deubiquitin
merscov
pl
pro
fig
supplementari
fig
howev
mycophenol
acid
found
unabl
inhibit
sarscov
pl
pro
even
concentr
mm
nevertheless
show
dosedepend
inhibitori
effect
mutant
sarscov
pl
pro
fig
residu
merscov
pl
pro
also
arginin
suggest
mycophenol
acid
abl
recogn
posit
charg
residu
pl
pro
among
three
inhibitor
ic
valu
lm
mycophenol
acid
ic
lm
tabl
comparison
nem
commonli
use
cystein
proteas
inhibitor
act
coval
modifi
activesit
cy
proteas
chou
et
al
also
verifi
inhibitor
merscov
pl
pro
time
ic
lm
tabl
compar
nem
effect
inhibitor
merscov
pl
pro
mycophenol
acid
less
effect
inhibitor
merscov
pl
pro
understand
kinet
mechan
involv
interact
compound
merscov
pl
pro
proteolyt
activ
enzym
measur
use
seri
peptidyl
substrat
concentr
variou
inhibitor
concentr
inhibit
data
global
fit
possibl
kinet
model
competit
noncompetit
uncompetit
simpl
competit
inhibit
pattern
best
describ
experiment
data
obtain
fig
fig
doubl
reciproc
plot
show
line
intercept
yaxi
contrast
noncompetit
inhibit
pattern
best
describ
inhibit
caus
mycophenol
acid
doubl
reciproc
plot
show
line
intercept
xaxi
fig
best
fit
eq
experiment
data
obtain
use
eq
experiment
data
obtain
use
mycophenol
acid
yield
inhibit
constant
k
valu
lm
respect
tabl
summar
tabl
micha
constant
k
peptidyl
substrat
hydrolysi
absenc
presenc
inhibitor
rang
lm
k
cat
valu
rang
min
k
peptidyl
substrat
higher
k
k
peptidyl
substrat
lower
k
mycophenol
acid
result
differ
inhibit
mechan
work
thiopurin
analog
mycophenol
acid
present
rais
interest
character
mutual
bind
effect
two
kind
compound
result
carri
multipl
inhibit
assay
yonetani
theorel
shown
fig
experi
carri
measur
initi
reaction
veloc
pl
pro
variou
concentr
mycophenol
acid
either
present
substrat
concentr
held
constant
subsatur
level
allow
inhibitor
bind
enzym
benson
et
al
fit
data
eq
result
show
line
intersect
x
axi
use
yonetanitheorel
plot
valu
mycophenol
acid
combin
mycophenol
acid
combin
fig
b
find
show
bind
mycophenol
acid
thiopurin
togeth
result
synergist
enhanc
inhibit
effect
pair
drug
merscov
pl
pro
hand
analysi
carri
use
variou
concentr
nem
either
fig
mycophenol
acid
fig
result
differ
interestingli
data
point
variou
nem
form
parallel
line
fig
bestfit
valu
one
nearli
infinit
find
indic
nem
bind
mutual
exclus
fashion
copeland
base
result
fact
nem
coval
bind
cystein
residu
activ
site
support
hypothesi
also
bind
enzym
catalyt
triad
result
inhibitori
effect
hand
bind
synergi
assay
use
variou
concentr
nem
presenc
mycophenol
acid
show
bestfit
line
intersect
x
axi
yonetanitheorel
plot
valu
fig
find
indic
bind
nem
mycophenol
acid
similar
find
mycophenol
acid
name
nem
mycophenol
acid
also
abl
synergist
increas
merscov
pl
pro
inhibit
gain
insight
inhibit
mechan
perform
dock
experi
use
mycophenol
acid
merscov
pl
pro
compound
abl
inhibit
deubiquitin
proteolyt
activ
enzym
suggest
bind
may
close
bind
site
ub
tail
ub
core
residu
therefor
space
near
catalyt
triad
put
subsit
chosen
dock
site
best
dock
score
mycophenol
acid
bind
merscov
pl
pro
respect
moreov
bind
energi
mycophenol
acid
pl
pro
kcalmol
respect
interestingli
importantli
dock
site
two
compound
quit
differ
fig
fit
well
caviti
near
catalyt
triad
pl
pro
abl
make
hydrogenbond
interact
residu
put
bind
site
close
found
sarscov
pl
pro
fig
carbon
atom
color
gray
chou
et
al
drug
bind
hydrogenbond
interact
enzym
may
interfer
proton
transfer
thio
group
imidazol
ring
like
bring
failur
catalysi
contrast
mycophenol
acid
found
show
hydrogenbond
interact
residu
hydrophob
contact
residu
fig
term
comparison
sarscov
pl
pro
pocket
close
residu
sarscov
pl
pro
howev
sarscov
pl
pro
use
dock
mycophenol
acid
fail
find
abl
explain
mycophenol
acid
show
inhibitori
effect
merscov
pl
pro
sarscov
furthermor
compar
find
structur
coronavir
mycophenol
acid
merscov
pl
pro
inhibit
sarscov
pl
pro
nd
b
peptid
substrat
dabcylfrlkggapikgvedan
lm
ubafc
lm
use
ic
assay
respect
assay
repeat
sever
time
ensur
reproduc
b
determin
locat
mycophenol
acid
dock
site
found
close
put
subsit
pl
pro
suggest
mycophenol
acid
abl
interfer
bind
orient
substrat
residu
overal
fact
found
distinct
bind
site
compound
studi
conform
synergist
inhibit
merscov
pl
pro
use
clinic
treat
cancer
sinc
present
hundr
relat
studi
publish
everi
year
includ
metabol
pharmacokinet
dosag
well
use
variou
therapi
target
cancer
rheumatoid
arthriti
system
lupu
erythematosu
crohn
diseas
karran
attard
recent
propos
mean
treat
wide
varieti
cancer
high
frequenc
homozyg
delet
gene
encod
methylthioadenosin
phosphorylas
includ
leukemia
glioblastoma
lung
cancer
pancreat
squamou
cell
carcinoma
other
munshi
et
al
addit
prodrug
azathioprin
also
use
mani
year
immunosuppress
treat
organ
transplant
recipi
karran
attard
furthermor
previou
studi
suggest
reason
select
inhibitor
pl
pro
inhibit
cystein
proteas
coronavir
main
proteas
cathepsin
b
k
l
papain
chou
et
al
recent
identifi
protect
effect
influenza
viru
albeit
high
ec
lm
low
select
index
chan
et
al
studi
suggest
thiopurin
broadspectrum
activ
like
suitabl
progenitor
develop
anticanc
antivir
drug
immunosuppress
mycophenol
acid
shown
broad
activ
vitro
andor
anim
model
differ
virus
includ
chikungunya
viru
khan
et
al
dengu
viru
diamond
et
al
japanes
enceph
viru
sebastian
et
al
west
nile
morrey
et
al
yellow
fever
viru
leyssen
et
al
possibl
hepat
b
viru
pan
et
al
recent
yuen
colleagu
hong
kong
found
combin
mycophenol
acid
interferon
abl
synergist
inhibit
replic
merscov
vero
cell
albeit
pharmacolog
mechan
action
remain
unknown
chan
et
al
investig
whether
mycophenol
acid
abl
synergist
inhibit
merscov
pl
pro
present
studi
provid
molecular
basi
design
effect
pl
pro
inhibitor
mer
highli
effect
sarscov
pl
pro
inhibitor
whose
bind
site
site
also
noncompetit
inhibit
mechan
lee
et
al
signific
differ
subsit
well
loop
sarscov
merscov
pl
pro
unlik
deriv
also
inhibit
merscov
pl
pro
lei
et
al
howev
discoveri
fact
differ
compound
panel
c
bestfit
noncompetit
inhibit
eq
r
sqr
respect
assay
repeat
sever
time
ensur
reproduc
kinet
paramet
k
k
cat
k
best
fit
shown
tabl
fig
b
c
presenc
mycophenol
acid
kinet
data
determin
noncompetit
inhibit
model
eq
fig
abl
bind
similar
region
within
merscov
pl
pro
expect
base
select
inhibitori
effect
mycophenol
acid
merscov
pl
pro
sarscov
pl
pro
mutant
fig
conclud
mycophenol
acid
abl
recogn
posit
charg
residu
near
subsit
baileyelkin
et
al
chou
et
al
inde
dock
experi
suggest
bind
site
mycophenol
acid
quit
close
subsit
moreov
mycophenol
acid
inhibit
sarscov
pl
pro
find
may
use
explain
mycophenol
acid
ineffect
sarscov
use
anim
model
barnard
et
al
although
affin
mycophenol
acid
respect
merscov
pl
pro
weak
drug
use
lead
compound
allow
optim
enhanc
potenc
hand
anoth
studi
shown
mycophenol
acid
effect
inhibit
merscov
replic
vero
cell
ec
lm
chan
et
al
conflict
find
low
dose
suggest
mycophenol
acid
may
one
inhibitori
target
addit
effect
merscov
present
potent
inhibitor
target
merscov
pl
pro
present
studi
found
one
noncompetit
inhibitor
mycophenol
acid
two
competit
inhibitor
target
merscov
pl
pro
synergist
thiopurin
mycophenol
acid
still
use
extens
rang
clinic
set
particularli
decid
leukemia
treatment
immunosuppress
studi
emphas
need
studi
depth
vivo
activ
drug
combin
evalu
potenti
therapeut
effect
commerci
avail
drug
term
vitro
activ
may
need
viru
abl
dock
mycophenol
acid
merscov
pl
pro
dock
carbon
color
orang
mycophenol
acid
magenta
merscov
pl
pro
cyan
pdb
code
perform
ds
model
softwar
accelri
dock
model
sarscov
pl
pro
gray
overlaid
comparison
dot
line
show
hydrophil
interact
pl
pro
inhibitor
abl
target
catalyt
triad
merscov
pl
pro
instead
mycophenol
acid
locat
far
catalyt
triad
show
hydrogen
bond
interact
residu
sarscov
pl
pro
accord
structur
sarscov
pl
pro
complex
ub
dock
site
mycophenol
acid
near
put
subsit
wherea
may
occupi
subsit
figur
produc
use
pymol
http
wwwpymolorg
interpret
refer
color
figur
legend
reader
refer
web
version
articl
spread
global
continu
pose
signific
threat
world
health
world
economi
